BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr Treat Options Gastro 2006;9:484-96. [DOI: 10.1007/s11938-006-0005-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Van Biervliet S, Vanbillemont G, Van Biervliet J, Declercq D, Robberecht E, Christophe A. Relation between Fatty Acid Composition and Clinical Status or Genotype in Cystic Fibrosis Patients. Ann Nutr Metab 2008;51:541-9. [DOI: 10.1159/000114208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
2 Atlas AB, Rosh JR. Cystic Fibrosis and Congenital Anomalies of the Exocrine Pancreas. Pediatric Gastrointestinal and Liver Disease. Elsevier; 2011. pp. 890-904.e5. [DOI: 10.1016/b978-1-4377-0774-8.10081-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Palaniappan SK, Than NN, Thein AW, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2020;3:CD012056. [PMID: 32227478 DOI: 10.1002/14651858.CD012056.pub3] [Reference Citation Analysis]
4 Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2017;8:CD012056. [PMID: 28850173 DOI: 10.1002/14651858.CD012056.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Ledder O, Haller W, Couper RT, Lewindon P, Oliver M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol 2014;29:1954-62. [PMID: 25238538 DOI: 10.1111/jgh.12785] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
6 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J. 2008;411:1-18. [PMID: 18333835 DOI: 10.1042/bj20071570] [Cited by in Crossref: 217] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
7 Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. Clin Chem Lab Med. 2010;48:1751-1755. [PMID: 20961201 DOI: 10.1515/cclm.2010.336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
8 Collardeau-Frachon S, Bouvier R, Le Gall C, Rivet C, Cabet F, Bellon G, Lachaux A, Scoazec JY. Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases. Virchows Arch 2007;451:57-64. [PMID: 17554556 DOI: 10.1007/s00428-007-0434-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kotb MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914. [PMID: 22942741 DOI: 10.3390/ijms13078882] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
10 Messick J. A 21st-century approach to cystic fibrosis: optimizing outcomes across the disease spectrum. J Pediatr Gastroenterol Nutr 2010;51 Suppl 7:S1-7; quiz 3 p following S7. [PMID: 20739870 DOI: 10.1097/MPG.0b013e3181ec0242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med. 2008;10:851-868. [PMID: 19092437 DOI: 10.1097/gim.0b013e31818e55a2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]